595 results match your criteria Cardiovascular Therapeutics[Journal]
Cardiovasc Ther 2018 Jun 8:e12444. Epub 2018 Jun 8.
Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.
The study by Kim et al. has substantial novelty: it addresses the issue of statin administration in patients with >3 x upper normal limit (UNL) alanine transaminase (ALT) activity at baseline. Most of patients with >3 x UNL ALT activity before statin treatment are expected to have non-alcoholic fatty liver disease (NAFLD). Read More
Cardiovasc Ther 2018 Jun 5:e12442. Epub 2018 Jun 5.
Department of Cardiology, National University Heart Centre, Singapore.
Aim: Compared with second-generation durable polymer drug-eluting stents (DP-DES), the cost-effectiveness of biodegradable polymer drug-eluting stents (BP-DES) remains unclear in the real-world setting. We assessed the cost-effectiveness of BP-DES in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).
Methods: We developed a decision-analytic model to compare the cost-effectiveness of BP-DES to DP-DES over one year and five years from healthcare payer perspective. Read More
Cardiovasc Ther 2018 Jun 5:e12441. Epub 2018 Jun 5.
General Hospital of Shenyang Military Region, Shenyang, China.
Background: The prognosis of patients with coronary artery disease (CAD) at hospital discharge was constantly varying, and post-discharge risk of ischemic events remain a concern. However, risk prediction tools to identify risk of ischemia for these patients has not yet been reported.
Aims: We sought to develop a scoring system for predicting long-term ischemic events in CAD patients receiving antiplatelet therapy that would be beneficial in appropriate personalized decision-making for these patients. Read More
Cardiovasc Ther 2018 Jun 4:e12439. Epub 2018 Jun 4.
Cardiovascular Department, Lady Davis Carmel Medical Center, Haifa, Israel and Clalit Health Services, Haifa and Western Galilee District.
Aim: PCSK9 inhibitors (PCSK9i) effectively lower cholesterol levels in randomized trials with reduction in cardiovascular outcomes and favorable safety profile. However, the access to PCSK9i is limited due to high cost and data regarding the use of PCSK9i in real-world practice is limited.
Methods: Data on all patients submitted for approval of PCSK9i at a regional lipid clinic, outside of clinical trials. Read More
Cardiovasc Ther 2018 Jun 4:e12440. Epub 2018 Jun 4.
Department of cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Aim: To evaluate the incidence, predictors and outcomes of post-discharge gastrointestinal bleeding (GIB) in patients underwent percutaneous coronary intervention (PCI) in a 2-year follow-up study.
Methods And Results: All consecutive patients who underwent PCI throughout 2013 were enrolled. Multivariable cox proportional hazards regression were used to identify predictors of post-discharge GIB and two year major adverse cardiovascular and cerebrovascular events (MACCE). Read More
Cardiovasc Ther 2018 May 30:e12438. Epub 2018 May 30.
ORAS Rehabilitation Hospital, Motta di Livenza, Treviso, Italy.
Introduction: Vitamin K antagonists, such as warfarin, are known to promote arterial calcification through blockade of gamma-carboxylation of Matrix-Gla-Protein. It is currently unknown whether other oral anticoagulants such as direct inhibitors of Factor Xa can have protective effects on the progression of aortic valve calcification.
Aims: to compare the effect of warfarin and rivaroxaban on the progression of aortic valve calcification in atherosclerotic mice. Read More
Cardiovasc Ther 2018 May 24:e12436. Epub 2018 May 24.
Institue for translational medicine, Qingdao University, 266021, People's Republic of China.
Atherosclerosis is one of the major macrovascular complications of diabetes mellitus (DM) and it is the main cause of death from clinical observation. Among various cell types involved in this disorders, endothelia cells, vascular smooth muscle cells (VSMC) and macrophages play crucial role in the occurrence and development of this disease. The regulation and stabilization of these cells are a key therapeutic strategy for DM associated atherosclerosis. Read More
Cardiovasc Ther 2018 May 24:e12437. Epub 2018 May 24.
Department of Arrhythmia, State Key Laboratory of Cardiovascular Disease, National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College.
Aim: Median nerve stimulation (MNS) is a novel neuromodulation approach for treatment of ventricular arrhythmia, but little is known about its chronic effects. The aim of this study was to investigate the effects of chronic MNS on ventricular arrhythmia and ventricular dysfunction post-myocardial infarction (MI).
Method: Two weeks after MI, twelve rabbits were randomly divided into control and MNS groups, and chronic MNS was performed in MNS group for two weeks. Read More
Cardiovasc Ther 2018 May 17:e12435. Epub 2018 May 17.
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Background: Major classes of medical therapy for heart failure with reduced ejection fraction (HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan remains unstudied.
Methods: We performed a single-center, prospective assessor-blinded study to determine the reverse remodeling response of sacubitril/valsartan therapy in HFrEF patients with a class I indication (New York heart Association [NYHA]-class II-IV, Left ventricular ejection fraction [LVEF] < 35%, optimal dose with Renin-Angiotensin-System-Blocker [RAS-blocker]). Read More
Cardiovasc Ther 2018 May 12:e12434. Epub 2018 May 12.
Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.
Aim: To examine the interference of β-blockers with the chemokine stromal cell-derived factor-1 (SDF-1) found in cell homing receptors, C-X-C chemokine receptor type 4 (CXCR-4) and CXCR-7, and regulatory proteins of homing pathways, we administered atenolol, carvedilol, metoprolol, and propranolol for 30 days using an orogastric tube to hypertensive rats.
Method: We collected blood samples before and after treatment and quantified the levels of SDF-1 with enzyme-linked immunosorbent assay (ELISA). On day 30 of treatment, the spontaneously hypertensive rats (SHR) were euthanized, and heart, liver, lung, and kidney tissues were biopsied. Read More
Cardiovasc Ther 2018 Apr 22:e12433. Epub 2018 Apr 22.
Coronary Research Group, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Introduction: There is potential value in testing individual response to P2Y12 inhibitors to predict ischemic and bleeding risk in patients undergoing percutaneous coronary intervention. The aims of this study were: (1) to validate the ability of a novel point of care (POC) assay, thrombelastography (TEG) 6s, to detect changes in adenosine diphosphate (ADP)-induced whole blood clotting in volunteers and patients given clopidogrel using TEG 5000 as a reference and (2) to compare a novel, rapid parameter, area under the curve at 15 minutes (AUC15), with the traditional maximum clot amplitude (MA) in TEG 6s.
Methods: A total of 25 participants were included in whom ADP-induced clotting was measured at 4 time points: (1) 12 healthy volunteers given 600 mg of clopidogrel; (2) 12 patients with ACS given 600 mg of clopidogrel; (3) 1 healthy volunteer given 600 mg of clopidogrel on 5 separate occasions. Read More
Cardiovasc Ther 2018 Apr 19:e12432. Epub 2018 Apr 19.
Department of Pharmacology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Aim: Oxidative stress and endothelial dysfunction are two inter-related conditions commonly seen in patients with cardiovascular risk factors. The enzyme, xanthine oxidase, is an important contributor to these phenomena but to a variable degree in different patient populations. This meta-analysis will summarize the effect of allopurinol, an established xanthine oxidase inhibitor, on endothelial function among patients with different comorbidities. Read More
Cardiovasc Ther 2018 Apr 14:e12331. Epub 2018 Apr 14.
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Heat shock proteins (HSPs) are an important family of protective proteins. They are involved actively in an array of cellular processes, including protective effects on the cardiovascular system in response to various stimuli. Increasing evidence shows that pharmacologic interventions that induce expression of HSPs may be a novel approach for the treatment of cardiovascular diseases. Read More
Cardiovasc Ther 2018 Jun 25;36(3):e12330. Epub 2018 Apr 25.
1st Department of Cardiology, Medical School, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Aim: High position of the self-expandable bioprosthesis CoreValve/Evolut R has been proved to affect immediate hemodynamics of the valve. Whether this may have any impact on long-term procedural outcome has not been defined yet. The purpose of this study was to assess whether the final position of aortic bioprosthesis affects its long-term functionality. Read More
Cardiovasc Ther 2018 Jun 24;36(3):e12329. Epub 2018 Apr 24.
Departments of Pediatrics, Physiology and Pharmacology, University of Montreal, Montreal, QC, Canada.
Aim: Excess angiogenesis or neovascularization plays a key role in the pathophysiology of several ocular diseases such as retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration. microRNA-181a (miR-181a) was found highly expressed in retina and choroidal tissues. This study intends to investigate the role of miR-181a in the regulation of ocular neovascularization in different pathophysiological conditions. Read More
Cardiovasc Ther 2018 Jun 19;36(3):e12328. Epub 2018 Apr 19.
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Background: Adenosine is a breakdown product of adenosine triphosphate and plays an important role in pharmacological preconditioning. The cardioprotective effects of adenosine preconditioning are well established. However, the possible mechanisms need to be explored. Read More
Cardiovasc Ther 2018 Jun 25;36(3):e12327. Epub 2018 Mar 25.
The 254th Hospital of PLA, Tianjin, China.
Aims: We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent.
Methods And Results: Patients (n = 419) scheduled to undergo percutaneous coronary intervention (PCI) were randomized to receive either the EXCEL 2 stent (n = 208) or the EXCEL stent (n = 211) from 15 Chinese centers. At 9 months, primary endpoint in-stent late loss (LL) difference was -0. Read More
Cardiovasc Ther 2018 Jun 25;36(3):e12326. Epub 2018 Mar 25.
Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Introduction: Sotalol and verapamil alone reduce reentry incidence during ventricular fibrillation (VF). We tested whether the combination of these two drugs had a synergistic effect on initiation, maintenance, and termination of VF.
Methods: Six open-chest pigs received intravenous sotalol (1. Read More
Cardiovasc Ther 2018 Jun 7;36(3):e12322. Epub 2018 Mar 7.
Vascular Biology Lab, Institute of Experimental Medicine and Biology of Cuyo (IMBECU) CONICET, School of Medical Sciences, National University of Cuyo, Mendoza, Argentina.
Aim: Perivascular adipose tissue (PVAT) is in intimate contact with the vessel wall and extravascular PVAT-derived inflammatory mediators may adversely influence atherosclerotic plaque formation and stability through outside-to-inside signaling. We sought to investigate the role of PVAT on the atheroma development in an experimental animal model of metabolic syndrome (MS) associated with oxidative stress and low-grade inflammatory state. We also studied the effect of pioglitazone an insulin sensitizer, on the aortic wall and its surrounding PVAT, considering a bi-directional communication between both layers. Read More
Cardiovasc Ther 2018 Jun 5;36(3):e12325. Epub 2018 Mar 5.
Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Aim: The bisoprolol transdermal patch is a newly developed β-blocker designed to deliver its pharmaceutical ingredient through the skin surface. We aimed to compare the bisoprolol transdermal patch and bisoprolol fumarate tablet using the heart rate variability (HRV).
Method: Eligible hypertensive patients received a 2-week administration with a 2. Read More
Cardiovasc Ther 2018 Jun 6;36(3):e12324. Epub 2018 Mar 6.
Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Aim: Prescription of statins to patients with chronic liver disease whose alanine transaminase (ALT) is over three times the upper normal limit (UNL) is not recommended. In this study, we attempted to evaluate patients with baseline ALT levels > 3 × UNL who were prescribed statins without ethical problems, using electronic medical records.
Methods: We enrolled subjects with ALT levels > 3 × UNL. Read More
Cardiovasc Ther 2018 Jun 6;36(3):e12323. Epub 2018 Mar 6.
Cardiology Unit, University and ASST Spedali Civili, Brescia, Italy.
Aim: Heart rate (HR) is an important prognostic factor in patients affected by chronic heart failure (CHF); ivabradine has been demonstrated to significantly reduce nonfatal myocardial infarction and hospitalization rate for acute heart failure and to improve left ventricular (LV) reverse remodeling, quality of life, exercise capacity, and arterial elastance (Ea) in these patients. We aimed at evaluating the short-term effects of ivabradine on ventricular-arterial coupling (VAC), aortic stiffness, and endothelial function in stable patients with CHF.
Methods: We evaluated 30 consecutive CHF patients (LVEF≤ 35%, NYHA class II) with sinus rhythm and HR ≥ 70 bpm on optimized pharmacological therapy. Read More
Cardiovasc Ther 2018 Jun 2;36(3):e12321. Epub 2018 Mar 2.
Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China.
Introduction: Atrial structural remodeling in the form of fibrosis contributes to the arrhythmic substrate in atrial fibrillation (AF). The aim of this study was to investigate the effects of doxycycline on chronic intermittent hypoxia (CIH)-induced atrial fibrosis and the pathophysiological mechanisms underlying such changes.
Methods: A total of 30 Sprague Dawley rats were randomized into three groups: control group, CIH group, and CIH with doxycycline treatment (CIH-D) group. Read More
Cardiovasc Ther 2018 Apr 8;36(2). Epub 2018 Feb 8.
Department of Physiology and Pathophysiology, School of Basic Medical Science, Tianjin Medical University, Heping, Tianjin, China.
Background: Myocardial infarction (MI) remains the most common cause of heart failure (HF) worldwide. For almost 50 years, HF has been recognized as a determinant of adverse prognosis after MI, but efforts to promote myocardial repair have failed to be translated into clinical therapies.
Aims: In this study, we investigated the effects of BRD4 on cardiac function and the underlying mechanism. Read More
Cardiovasc Ther 2018 Apr 30;36(2). Epub 2018 Jan 30.
Department of Cardiology, National University Heart Centre, Singapore City, Singapore.
Aims: The safety and efficacy of BP-DES compared to second-generation DP-DES remain unclear in the real-world setting. We compared the clinical outcomes of biodegradable polymer drug-eluting stents (BP-DES) with second-generation durable polymer drug-eluting stents (DP-DES) in an all-comer percutaneous coronary intervention (PCI) registry.
Methods/results: The study included a cohort of 1065 patients treated with either BP-DES or DP-DES from January 2009 through October 2015. Read More
Cardiovasc Ther 2018 Apr 14;36(2). Epub 2018 Feb 14.
Key Laboratory of Biochemistry, Wuhan People's Hospital, Wuhan, China.
Background/aims: Oxidative stress injury is believed to be important in diabetic cardiomyopathy. Recent evidence indicates that miR-22 plays an important role in various cardiovascular diseases, but the protective role of miR-22 in diabetic cardiomyopathy remains undetermined.
Methods: Diabetes was induced in male C57BL/6 mice by intraperitoneal injection with streptozotocin combined with a high-fat diet, and miR-22 was overexpressed following transfection with adeno-associated virus. Read More
Cardiovasc Ther 2018 Apr 24;36(2). Epub 2018 Jan 24.
Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Introduction: Cardiovascular disease is the main cause of mortality and morbidity in the industrialized world. Incretin-mimetic compounds such as exenatide are currently used in the treatment of type 2 diabetes.
Aims: We investigated the effects of incretin drugs on apoptosis, adhesion molecule expression, and concentration of extracellular matrix (ECM) metalloproteinases under inflammatory conditions within the context of atherosclerotic plaque formation of both human coronary artery endothelial cells (hCAECs) and human aortic endothelial cells (hAoECs). Read More
Cardiovasc Ther 2018 Apr 17;36(2). Epub 2018 Jan 17.
Department of nephrology, Affiliated Hospital of Jining Medical College, Jining, China.
Introduction: Nicorandil has been suggested as a preventative strategy against the incidence of contrast-induced nephropathy (CIN). However, results of relevant randomized controlled trials (RCTs) were inconsistent.
Aims: We performed a meta-analysis of RCTs to evaluate the preventive efficacy of periprocedural treatment of nicorandil against the incidence of CIN. Read More
Cardiovasc Ther 2018 Apr 3;36(2). Epub 2018 Jan 3.
Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
Aim: This study was conducted to compare predictive accuracy of the available pharmacogenetics (PGx)-guided warfarin dosing algorithms derived from Caucasian, Asian, and mixed population to identify a suitable algorithm for Thai population.
Methods: Ten warfarin dosing algorithms derived from different population including Caucasian, East Asian, South-East Asian, and mixed races were selected and tested with clinical and genetic data of Thai patients. Comparative performances of these algorithms were tested using mean dose error (MDE) between actual warfarin maintenance dose (AWMD) and predicted dose generated by each dosing algorithm, and percentage of ideal dose prediction (IDP). Read More
Cardiovasc Ther 2018 Feb 22;36(1). Epub 2017 Dec 22.
Pediatric Cardiology Unit, Department of Women's and Children's Health, University of Padua, Padua, Italy.
Introduction: The Fontan procedure is the palliative procedure for single ventricle physiology. Pulmonary resistance plays a key role in the success of this operation. There are conflicting data concerning the impact of pulmonary vasodilators on survival and functional capacity among Fontan patients. Read More
Cardiovasc Ther 2018 Feb 9;36(1). Epub 2017 Dec 9.
Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Background: The development of heart failure after acute myocardial infarction (MI) was related to left ventricular (LV) pathological remodeling and dysfunction. Cardiac stem cells (CSCs) provided a new option to treat acute MI. This study was to investigate the effects of CSCs on structural and functional alteration in acute MI. Read More
Cardiovasc Ther 2018 Feb 3;36(1). Epub 2017 Dec 3.
Department of Internal Medicine B, Ziv Medical Center, Safad, Israel.
Purpose: Pulmonary Hypertension (PH) is complex disease which is associated with endothelial and cardiac dysfunction. Tetrahydrobiopterin (BH ) regulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide rather than superoxide which maintains normal endothelial and cardiac function. This study explores the therapeutic potential of BH in experimental PH. Read More
Cardiovasc Ther 2018 Feb 26;36(1). Epub 2017 Nov 26.
Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
The role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome X has recently been recognized. Allopurinol has previously been shown to improve endothelial dysfunction, reduce oxidative stress burden, and improve myocardial efficiency. In this "proof of concept" study, we investigated the effect of allopurinol on exercise capacity, coronary and peripheral endothelial function, and serum B-type natriuretic peptide (BNP: a marker of cardiac function and myocardial ischemia) in patients with cardiac syndrome X. Read More
Cardiovasc Ther 2018 Feb 23;36(1). Epub 2017 Nov 23.
Pfizer Inc., South San Francisco and San Diego, CA, USA.
Aims: Three single-dose and one multiple-dose phase I studies were conducted in subjects with primary hypercholesterolemia to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Methods: The dosing schedules for hypercholesterolemic subjects randomized in the four phase I studies were (1) ascending, single, intravenous (IV) bococizumab (0.3, 1, 3, 6, 12, or 18 mg/kg), or placebo (N = 48; baseline low-density lipoprotein cholesterol [LDL-C] ≥130 mg/dL); (2) single, IV bococizumab (0. Read More
Cardiovasc Ther 2018 Feb 11;36(1). Epub 2017 Nov 11.
Department of Cardiac, Thoracic and Vascular Sciences, Cardiology Clinic, University of Padua, Padua, Italy.
Introduction: The issue of anticoagulation in individuals with nonvalvular atrial fibrillation (NVAF) and 1 non-gender-related (NGR) risk factor is subject to debate. The reported risk of stroke in untreated individuals is not uniform, and the rate of hemorrhage associated with anticoagulation in this group of individuals is not well defined. To this end, we assessed the rate of stroke and major hemorrhage in individuals treated with warfarin. Read More
Cardiovasc Ther 2018 Feb 25;36(1). Epub 2017 Nov 25.
Pfizer Inc., South San Francisco and San Diego, CA, USA.
Aims: Two multiple-dose phase II studies were conducted in subjects with primary hypercholesterolemia to evaluate the LDL-C lowering efficacy, safety, and tolerability of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.
Methods: The results from the two phase II, double-blinded, randomized, placebo-controlled, multicenter studies conducted in the USA and Canada were combined. In Study 1, 90 subjects with LDL-C ≥100 mg/dL received intravenous (IV) placebo or bococizumab 0. Read More
Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Aim: The influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia.
Method: Hypercholesterolemic nondiabetic (HC, n = 37) and diabetic (DM, n = 47) patients were treated with simvastatin (SV, 10 or 20 mg/d/8-wk) and then SV plus ezetimibe (SV + EZ, 10 mg each/d/4 wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. Read More
Cardiovasc Ther 2017 Dec 4;35(6). Epub 2017 Oct 4.
Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Vic., Australia.
Introduction: Hyperhomocysteinemia (HHcy) impairs nitric oxide endothelium-dependent vasodilation, consequently leading to atherosclerosis, a risk factor for cardiovascular disease. Novel treatments for HHcy are necessary.
Aim: We tested the hypothesis that alamandine, a vasoactive peptide of the renin-angiotensin system (RAS), could reverse HHcy-induced vascular dysfunction through the MrgD receptor and that this is mediated by the protein kinase A (PKA) pathway. Read More
Cardiovasc Ther 2017 Dec 27;35(6). Epub 2017 Sep 27.
Stem Cell and Biotheraphy Technology Research Center, Xinxiang Medical University, Xinxiang, China.
Background/aims: The differentiation efficiency of bone marrow mesenchymal stem cells (BM-MSCs) is low in vivo after transplantation. Therefore, it is necessary to look for effective reagents for enhancing cardiac differentiation of BM-MSCs. It has been reported that cardiac differentiation of stem cells depends on the activation of extracellular signal-regulated protein 1/2 (ERK1/2) signaling. Read More
Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
Pharmacy, School of Medicine, University of Tasmania, Hobart, Tas, Australia.
Background: Patients' knowledge regarding their oral anticoagulant (OAC) treatment for stroke prevention in atrial fibrillation (AF), their level of medication adherence, and health literacy are known to affect treatment outcomes. However, contemporary data regarding the relationships between these variables are lacking.
Objective: To investigate the relationships between anticoagulant knowledge, health literacy, and self-reported adherence in patients taking warfarin and the directly acting oral anticoagulants. Read More
Cardiovasc Ther 2017 Dec 3;35(6). Epub 2017 Oct 3.
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia.
Background: Available data on the prognosis of heart failure (HF) patients are predominantly limited to patients diagnosed at time of hospitalization.
Aims: To describe the long-term survival of incident HF patients and identify clinical characteristics associated with mortality.
Methods: The Second Australian National Blood Pressure Study (ANBP2) randomized 6083 hypertensive subjects aged 65-84 years to angiotensin-converting enzyme (ACE) inhibitor or thiazide diuretic-based therapy and followed them for a median of 4. Read More
Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
Aim: To investigate the effect of apolipoprotein E (APOE), cholesteryl ester transfer protein (CETP) and proprotein convertase subtilisin kexin type 9 (PCSK9) polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolemic patients.
Method: Two hundred and twenty-five hypercholesterolemic patients in southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day for 3 months. Serum lipids were measured before and after the therapy. Read More
Cardiovasc Ther 2017 Dec 26;35(6). Epub 2017 Sep 26.
Division of Population Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Aim: To explore the association between cardiovascular medication use and cognitive impairment in adults aged 50 years and over.
Method: This cross-sectional linked database study involved secondary quantitative analysis of 1903 participants from wave 1 of the Irish Longitudinal Study on Ageing with available pharmacy claims data. Cognitive impairment was assessed using a cut-off of ≤23 on the Montreal Cognitive Assessment. Read More
Cardiovasc Ther 2017 Dec 25;35(6). Epub 2017 Sep 25.
Department of Cardiology, Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Aim: To discuss the pathophysiology of iron metabolism in chronic heart failure (CHF) and the current knowledge of the efficacy of intravenous (IV) iron therapy in patients with CHF and identify points of controversy as well as highlight areas for future research.
Discussion: Iron deficiency is a recognized complication of many chronic conditions. Numerous studies have reported that iron deficiency is highly prevalent in patients with CHF and is associated with exercise intolerance, reduced quality of life, and increased risk of hospitalization and mortality. Read More
Cardiovasc Ther 2018 Feb 25;36(1). Epub 2017 Oct 25.
Department of Physiology, Kangwon National University School of Medicine, Chuncheon, South Korea.
Aims: We investigated the vasorelaxant effect of nateglinide and its related mechanisms using phenylephrine (Phe)-induced precontracted aortic rings.
Methods: Arterial tone measurement was performed in aortic smooth muscle.
Results: The application of nateglinide induced vasorelaxation in a concentration-dependent manner. Read More
Cardiovasc Ther 2017 Dec;35(6)
Qindao University Medical College Affiliated Yantai Yuhuangding Hospital, Yantai, Shandong, China.
Introduction: Pregnancy is associated with a hypercoagulable state, which makes pregnant women with prosthetic heart valves at high risk of thromboembolism. The proper anticoagulation regimen should take both the maternal protection and the fetal outcomes into consideration. However, no consensus on the present anticoagulation regimen for those women has been reached yet, especially in the first trimester of pregnancy. Read More
Cardiovasc Ther 2017 Oct;35(5)
Division of Cardiology, Department of Internal Medicine/Cardiovascular Center, Seoul National University Hospital, Seoul, Korea.
Introduction And Aims: Endothelial dysfunction and arterial stiffness have a prognostic value on adverse long-term outcomes in coronary artery disease (CAD) patients. We evaluated the efficacy on vascular reactivity of candesartan and analyzed predictors to control the candesartan's effect on vascular reactivity in CAD patients.
Method: Patients were prospectively enrolled and prescribed candesartan for 6 months. Read More
Cardiovasc Ther 2017 Dec;35(6)
Division of Cardiology, Department of Internal Medicine, Baylor Heart and Vascular Institute, Baylor University Medical Center at Dallas, Dallas, TX, USA.
Introduction: Coronary chronic total occlusions (CTOs) are commonly encountered during diagnostic angiograms. With recent advances, especially in experienced centers, success rates with CTO percutaneous coronary intervention (PCI) have approached 80% or higher. It is important to note that despite these advancements in techniques, CTOs remain difficult to treat. Read More
Cardiovasc Ther 2017 Oct;35(5)
Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Aim: Although the gold standard treatment for acute myocardial infarction is reperfusion therapy, reperfusion itself can cause myocardial damage via induction of cardiac mitochondrial dysfunction. This can lead to increased myocardial infarct size, arrhythmias, and left ventricular (LV) dysfunction. Recently, a newly discovered peptide, Humanin, has been shown to exert several beneficial effects including antioxidative and antiapoptosis effects. Read More
Cardiovasc Ther 2017 Oct;35(5)
Department of Physiology and Pharmacology and Post-Graduate Program in Cardiovascular Sciences, Fluminense Federal University, Niterói, Brazil.
Introduction: Parasympathetic dysfunction may play a role in the genesis of arrhythmias in Chagas disease.
Aim: This study evaluates the acute effects of pyridostigmine (PYR), a reversible cholinesterase inhibitor, on the occurrence of arrhythmias in patients with Chagas cardiac disease.
Method: Following a double-blind, randomized, placebo-controlled, cross-over protocol, 17 patients (age 50±2 years) with Chagas cardiac disease type B underwent 24-hour Holter recordings after oral administration of either pyridostigmine bromide (45 mg, 3 times/day) or placebo (PLA). Read More